Sign In
Buy AUTL
$1.62
-0.130 (-7.43%)
At Close: Jun 03, 2026
2020 Insights into the Global Multiple Myeloma Market and Competitive Landscape - ResearchAndMarkets.com
12:00am, Friday, 26'th Jun 2020
The
Autolus Therapeutics (AUTL) Gets a Buy Rating from Needham - Markets
04:51pm, Thursday, 25'th Jun 2020
Needham analyst Chad Messer maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a price
Autolus Therapeutics (AUTL) Received its Third Buy in a Row - Markets
03:22pm, Thursday, 25'th Jun 2020
After William Blair and Needham gave Autolus Therapeutics (NASDAQ: AUTL) a Buy rating last month, the company received another Buy,
Moving Average Crossover Alert: Autolus Therapeutics
01:32pm, Wednesday, 24'th Jun 2020
Autolus Therapeutics plc (AUTL) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
11:00am, Monday, 22'nd Jun 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced preclinical data related to AUTO5 in T cell lymphom
Is Autolus Therapeutics PLC Sponsored (AUTL) Stock Outpacing Its Medical Peers This Year?
03:30pm, Friday, 19'th Jun 2020
Is (AUTL) Outperforming Other Medical Stocks This Year?
Autolus Therapeutics (AUTL) Receives a Buy from Mizuho Securities - Markets
10:43am, Friday, 19'th Jun 2020
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Autolus Therapeutics (AUTL – Research Report) today and set a
Analysts' Top Healthcare Picks: Regeneron (REGN), IMARA (IMRA) - Markets
03:44pm, Friday, 12'th Jun 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
06:30am, Friday, 12'th Jun 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on its AUTO1 program
Global CAR-T Therapy Market Assessment 2020-2030 - ResearchAndMarkets.com
12:00am, Thursday, 11'th Jun 2020
The
Autolus Therapeutics reschedules its investor EHA conference call
09:00pm, Monday, 08'th Jun 2020
LONDON, June 08, 2020 -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today.
Industry Analysts Just Upgraded Their Autolus Therapeutics plc (NASDAQ:AUTL) Revenue Forecasts By -3.3%
10:28am, Wednesday, 03'rd Jun 2020
Autolus Therapeutics plc (NASDAQ:AUTL) shareholders will have a reason to smile today, with the analysts making...
Autolus Therapeutics' Shares March Higher, Can It Continue?
12:07pm, Tuesday, 02'nd Jun 2020
As of late, it has definitely been a great time to be an investor in Autolus Therapeutics.
Vivet Therapeutics meldete heute, dass sowohl die US-Food and Drug Administration (FDA) als auch die Europäische Kommission (EC) VTX-803, das zweite G
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
11:37am, Friday, 29'th May 2020
Autolus Therapeutics plc (AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced new data highlighting progress on AUTO3, the compan
